8-K: Veru Inc. Announces 1-for-10 Reverse Stock Split

Veru Inc. will implement a 1-for-10 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, effective August 8, 2025.

Summary

• Veru Inc. is implementing a 1-for-10 reverse stock split of its common stock.
• The reverse stock split will become effective at 11:59 p.m. CT on August 8, 2025.
• Beginning on or about August 11, 2025, the common stock is expected to trade on the Nasdaq Capital Market on a split-adjusted basis under the same symbol 'VERU' and new CUSIP number 92536C202.
• The primary reason for the reverse stock split is to enable the company to regain compliance with the Nasdaq $1.00 minimum bid price requirement.
• Shareholders approved a reverse stock split proposal on July 25, 2025, and the Board of Directors subsequently approved the 1-for-10 ratio.
• No fractional shares will be issued; shareholders will receive a cash payment in lieu of fractional shares.
• The reverse stock split will affect all shareholders uniformly and will not affect any shareholder's ownership percentage, except for those receiving cash for fractional shares.
• Proportionate adjustments will be made to outstanding equity awards and shares reserved for future issuance under the company's stock incentive plans.

Sentiment

Score: 3

Explanation: While the reverse stock split addresses Nasdaq compliance, the necessity of such an action typically indicates a significant decline in share price and underlying market concerns about the company's performance or prospects. It does not fundamentally change the company's valuation or operational health.

Positives

• The reverse stock split aims to regain compliance with the Nasdaq $1.00 minimum bid price requirement, which is crucial for maintaining the company's listing on the exchange.
• The split will not reduce the number of authorized shares of common stock or change its par value.
• The action affects all shareholders uniformly, preserving their ownership percentage (excluding fractional share adjustments).

Negatives

• The necessity of a reverse stock split typically indicates that the company's stock price has fallen significantly, often below exchange listing requirements, which can be perceived negatively by the market.
• The need for this corporate action suggests underlying challenges in maintaining a higher share price and investor confidence.

Risks

• Market conditions and their impact on the trading price of the company's common stock on the Nasdaq Capital Market.
• The development of the company's product portfolio and the results of clinical studies possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development.
• Inability to reach agreement with the FDA on study design requirements for planned clinical studies, including for the Phase 3 program for enobosarm and the number and cost of required Phase 3 studies.
• Potential delays in the timing of and results from clinical trials and studies, including as a result of an inability to enroll sufficient numbers of subjects or enroll subjects in accordance with planned schedules.
• The ability to fund planned clinical development as well as other operations of the company.
• The timing of any submission to the FDA or any other regulatory authority and any determinations made by them.
• The potential for disruptions at the FDA or other government agencies to negatively affect the business.
• Any products of the company, if approved, possibly not being commercially successful.
• The ability of the company to obtain sufficient financing on acceptable terms when needed to fund development and operations.
• Demand for, market acceptance of, and competition against any of the company's products or product candidates.
• New or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions.
• Changes in regulatory practices or policies or government-driven healthcare reform efforts, including pricing pressures and insurance coverage and reimbursement changes.
• The company's ability to protect and enforce its intellectual property.
• Costs and other effects of litigation, including product liability claims and securities litigation.
• The company's ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives.
• The company's ability to successfully integrate acquired businesses, technologies or products.

Future Outlook

The company expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market on August 11, 2025, under the same symbol 'VERU' and new CUSIP number 92536C202. The primary goal is to regain compliance with the Nasdaq $1.00 minimum bid price requirement.

Management Comments

• The company is primarily implementing the reverse stock split to enable it to regain compliance with the Nasdaq $1.00 minimum bid price requirement.

Industry Context

Reverse stock splits are common actions taken by companies, particularly in the biopharmaceutical sector, when their stock price falls below exchange minimums. This move aims to increase the per-share price to maintain listing compliance, which is vital for investor confidence and liquidity. While it doesn't change the company's underlying value, it can signal past performance challenges or a need to improve market perception.

Corporate Governance

Stakeholder Impact

• Shareholders: The number of shares held will decrease by a factor of 10, but their overall ownership percentage (excluding fractional shares) will remain the same. Shareholders entitled to fractional shares will receive a cash payment.
• Employees (holding equity awards): Outstanding stock options, stock appreciation rights, and equity incentive plans will be proportionally adjusted to reflect the new share structure.
• Nasdaq Capital Market: The action aims to ensure continued listing compliance, which is beneficial for the company's market presence and investor confidence.

Next Steps

• Trading on a split-adjusted basis on the Nasdaq Capital Market beginning August 11, 2025.
• Computershare Inc., the company's transfer agent, will send letters of transmittal to shareholders holding physical certificates with instructions on how to surrender them.
• Shareholders with book-entry shares or those holding shares through a bank, broker, or other nominee will not need to take any action.

Key Dates

Recommendation

The reverse stock split is a technical measure to maintain Nasdaq listing compliance, not an indicator of improved fundamental performance. While it addresses a critical listing requirement, it doesn't inherently change the company's underlying value or business prospects. Investors should hold and monitor future financial results and clinical trial progress to assess long-term viability.

Keywords

Veru Inc., Reverse Stock Split, Nasdaq Compliance, Biopharmaceutical, Stock Split, Corporate Action, VERU